A 2020 systematic review by Gorry et al38 that examined the cost-effectiveness of pharmacological treatments of advanced melanoma found that BRAF- and MEK-inhibitor doublet targeted therapy combinations, such as vemurafenib plus cobimetinib, compared with a BRAF monotherapy or chemotherapy, were consistently not cost-effective. The gene discussed is MAP2K7; the disease is melanoma.